Dapagliflozin

This page has yet to be adopted. If you would like to take it on please contact Anna Harding at contact@diapedia.org

Dapagliflozin is an SGLT2 inhibitor which was approved by the FDA in 2014 for once daily use in the management of type 2 diabetes. It is marketed under the trade name of FARZIGA in the USA and is marketed elsewhere as FORZIGA. In the UK it was approved by NICE in 2013 as monotherapy in those intolerant of metformin and as an add-on therapy for use in combination with metformin or insulin.